Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Dutasteride.

Hannah C Evans1, Karen L Goa

  • 1Adis International Limited, Auckland, New Zealand.

Drugs & Aging
|October 21, 2003
PubMed
Summary
This summary is machine-generated.

Dutasteride significantly reduces dihydrotestosterone levels and improves benign prostatic hyperplasia (BPH) symptoms. It also lowers the risk of acute urinary retention and BPH-related surgery, demonstrating sustained efficacy and tolerability.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Erratum to: Maclobemide.

Drugs·2017
Same author

Erratum to: Moclobemide.

Drugs·2017
Same author

Erratum to: Cyclosporin: A Review of its Pharmacodynamic and Pharmacokinetic Properties, and Therapeutic Use in Immunoregulatory Disorders.

Drugs·2017
Same author

Transdermal ethinylestradiol/norelgestromin: a review of its use in hormonal contraception.

Treatments in endocrinology·2005
Same author

Spotlight on insulin aspart in type 1 and 2 diabetes mellitus.

Treatments in endocrinology·2005
Same author

Spotlight on rosiglitazone in the management of type 2 diabetes mellitus.

Treatments in endocrinology·2005
Same journal

Targeted Treatment for Hyperuricemia: The Drug Pipeline.

Drugs & aging·2026
Same journal

Efficacy and Safety of Ciprofol Versus Propofol for Anesthesia in Older Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Drugs & aging·2026
Same journal

Leveraging Real-World Data for Clinical Decision Making in Geriatric Oncology.

Drugs & aging·2026
Same journal

Drug Utilisation of Fall-Risk-Increasing Drugs (FRIDs) and Risk of Hospitalisation: A Nested Case-Control Study Among Community-Dwelling Older Adults.

Drugs & aging·2026
Same journal

Gabapentinoid Use and Risk of Alzheimer's Disease-Related Dementias: A Systematic Review and Meta-analysis of Observational Studies.

Drugs & aging·2026
Same journal

Development and Validation of Prescribing Appropriateness Criteria (PAC) for Sri Lankan Older Adults.

Drugs & aging·2026
See all related articles

Area of Science:

  • Pharmacology
  • Urology

Background:

  • Benign prostatic hyperplasia (BPH) is a common condition in aging men.
  • 5alpha-reductase inhibitors are used to treat BPH by reducing prostate size.

Purpose of the Study:

  • To evaluate the efficacy and safety of dutasteride in patients with BPH.
  • To assess the long-term effects of dutasteride on prostate volume, urinary symptoms, and surgical risk.

Main Methods:

  • Combined analysis of three placebo-controlled clinical studies.
  • Administration of oral dutasteride 0.5 mg/day.
  • Assessment of dihydrotestosterone levels, American Urological Association- Symptom Index scores, urinary flow rate, prostate volume, and surgical outcomes.

Main Results:

Related Experiment Videos

  • Dutasteride reduced dihydrotestosterone levels by >90% in 85% of patients.
  • Sustained improvements in BPH symptoms and urinary flow rate observed over 2 years (p < 0.001).
  • Reduced risk of acute urinary retention (57%) and BPH-related surgery (48%) (p < 0.001).
  • Prostate and transition zone volumes were significantly reduced (p < 0.001).
  • Efficacy maintained for up to 4 years in an extension study.
  • Dutasteride monotherapy maintained symptom relief after combination treatment, except in severe cases.
  • Generally well-tolerated with low incidence of adverse events like impotence and reduced libido, which decreased over time.

    • Conclusions:

    • Dutasteride is an effective treatment for BPH, offering significant reductions in dihydrotestosterone, prostate volume, and urinary symptoms.
    • It substantially decreases the risk of acute urinary retention and BPH-related surgery.
    • Dutasteride demonstrates sustained efficacy and a generally favorable safety profile for long-term BPH management.